<?xml version='1.0' encoding='UTF-8'?>
<rss xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" version="2.0"><channel><title>Oncology</title><link>https://nrouizem.github.io/test/oncology_feed.xml</link><description>Daily curated &amp; summarized biopharma news.</description><atom:link href="https://nrouizem.github.io/test/oncology_feed.xml" rel="self"/><docs>http://www.rssboard.org/rss-specification</docs><generator>python-feedgen</generator><language>en</language><lastBuildDate>Thu, 20 Mar 2025 01:18:03 +0000</lastBuildDate><item><title>How Capsida’s unconventional funding strategy and capsid technology promise to reshape CNS treatments</title><link>https://www.drugdiscoverytrends.com/how-capsidas-unconventional-funding-strategy-and-capsid-technology-promise-to-reshape-cns-treatments/</link><description>Capsida Biotherapeutics announced that partner AbbVie will exercise its option on their first neurodegenerative disease program, resulting in a $40 million license payment. The startup has focused on building its financial resources through collaborations with major pharmaceutical companies rather than relying on conventional funding methods.</description><pubDate>Sat, 01 Feb 2025 21:05:12 +0000</pubDate></item><item><title>The FDA Fast-Tracked GNSC-001 gene therapy targets osteoarthritis at its root</title><link>https://www.drugdiscoverytrends.com/the-fda-fast-tracked-gnsc-001-gene-therapy-targets-osteoarthritis-at-its-root/</link><description>The FDA has fast-tracked GNSC-001, a groundbreaking gene therapy aimed at addressing osteoarthritis, a condition impacting over 30 million Americans and costing the healthcare system nearly $460 billion annually. This innovative treatment targets the disease at its core, promising a significant advancement in osteoarthritis management.</description><pubDate>Tue, 04 Feb 2025 19:16:27 +0000</pubDate></item><item><title>How to know if your biopharma company is ‘data ready’ and why it matters</title><link>https://www.drugdiscoverytrends.com/how-to-know-if-your-biopharma-company-is-data-ready-and-why-it-matters/</link><description>Ancient scrolls, possibly linked to Julius Caesar's father-in-law and buried by the eruption that destroyed Pompeii, have remained in storage since their discovery in the 1800s. Researchers are now beginning to carefully examine these historical texts, which have long been protected.</description><pubDate>Sat, 08 Feb 2025 18:20:30 +0000</pubDate></item><item><title>Avoiding aggregates: How new technology is helping mAb developers monitor a vital CQA</title><link>https://www.drugdiscoverytrends.com/avoiding-aggregates-how-new-technology-is-helping-mab-developers-monitor-a-vital-cqa/</link><description>The monoclonal antibodies (mAbs) market, currently valued at over $330 billion, is set to more than double by 2030, driven by a growing research pipeline. Developers are increasingly focusing on measuring and maintaining critical quality attributes (CQAs), with new technology emerging to help monitor vital aspects, such as preventing aggregates.</description><pubDate>Sat, 08 Feb 2025 19:54:03 +0000</pubDate></item><item><title>For sparse data classification, VersAI’s Extreme AutoML is more accurate and orders of magnitude faster than Google’s AutoML</title><link>https://www.drugdiscoverytrends.com/for-sparse-data-classification-versais-extreme-automl-is-orders-of-magnitude-faster-than-googles-automl/</link><description>Verseon's new AI technology, VersAI, is proving to be a significant challenger to deep learning methods by training predictive models much faster than Google AutoML, especially in scenarios with limited data. Researchers from Verseon and the Missouri University of Science and Technology highlighted its superior performance in a recent preprint, emphasizing its potential impact on data classification in drug discovery.</description><pubDate>Sun, 09 Feb 2025 19:59:12 +0000</pubDate></item><item><title>Complexity’s counterpoint: Understanding protocol optimization</title><link>https://www.drugdiscoverytrends.com/complexitys-counterpoint-understanding-protocol-optimization/</link><description>The clinical research landscape is experiencing a rise in protocol complexity, characterized by an increase in endpoints and procedures throughout all trial phases and therapeutic areas. This trend highlights the need for optimizing trial designs to effectively manage the challenges posed by more sophisticated protocols.</description><pubDate>Mon, 10 Feb 2025 20:33:52 +0000</pubDate></item><item><title>Flatiron Health sees shift from “what if” to “what is” in real-world evidence in oncology</title><link>https://www.drugdiscoverytrends.com/flatiron-health-sees-shift-from-what-if-to-what-is-in-real-world-evidence-in-oncology/</link><description>Flatiron Health, led by Blythe Adamson, is transforming cancer care with a focus on real-world evidence, as skepticism around AI in healthcare diminishes in the post-ChatGPT era. The company demonstrates the growing impact of data in oncology by shifting the conversation from speculative possibilities to concrete realities.</description><pubDate>Wed, 12 Feb 2025 03:39:41 +0000</pubDate></item><item><title>With Deep Research, the CEO of OMNY Health says we’re still ‘in the first inning’ of AI-assisted research</title><link>https://www.drugdiscoverytrends.com/with-deep-research-the-ceo-of-omny-health-says-were-still-in-the-first-inning-of-ai-assisted-research/</link><description>OpenAI's Deep Research tool is designed to streamline internet-based research by allowing users to assign tasks and receive comprehensive results within up to thirty minutes. The CEO of OMNY Health emphasizes that the capabilities of AI-assisted research are still in their early stages, suggesting significant potential for future development.</description><pubDate>Fri, 14 Feb 2025 00:05:54 +0000</pubDate></item><item><title>Atropos Health CEO Dr. Brigham Hyde on closing healthcare’s evidence gap with AI-driven insight</title><link>https://www.drugdiscoverytrends.com/atropos-health-ceo-dr-brigham-hyde-on-closing-healthcares-evidence-gap-with-ai-driven-insight/</link><description>Atropos Health CEO Dr. Brigham Hyde aims to close the “evidence gap” in modern medicine by leveraging AI-driven insights to enhance healthcare decision-making. His focus addresses the challenge of navigating limited guidance from clinical trials, ultimately improving patient outcomes.</description><pubDate>Fri, 14 Feb 2025 03:09:10 +0000</pubDate></item><item><title>The challenge of AI inventorship in healthcare</title><link>https://www.drugdiscoverytrends.com/the-challenge-of-ai-inventorship-in-healthcare/</link><description>Generative AI is revolutionizing drug discovery by speeding up the identification of new therapeutics, with several AI-assisted drugs currently in clinical trials. The rise of these advanced technologies also brings challenges regarding patent protection and the issue of AI inventorship in healthcare.</description><pubDate>Fri, 21 Feb 2025 14:15:42 +0000</pubDate></item><item><title>Redefining vaccine trial recruitment</title><link>https://www.fiercebiotech.com/resource/redefining-vaccine-trial-recruitment</link><description>Avacare Clinical Research Network's new white paper highlights innovative, data-driven strategies to tackle recruitment challenges and boost diversity in vaccine trials, ensuring more efficient and representative study outcomes. Sponsored by Avacare, the resource offers actionable insights for optimizing trial design and participant engagement through cutting-edge approaches.</description><pubDate>Wed, 26 Feb 2025 14:26:35 +0000</pubDate></item><item><title>Solutions for CAR-Engineered Cell Characterization</title><link>https://www.fiercebiotech.com/resource/solutions-car-engineered-cell-characterization</link><description>Cell Signaling Technology (CST) has unveiled purpose-built tools, including recombinant antibodies targeting scFv linkers like G4S and Whitlow/218, to accelerate CAR-engineered cell characterization and development. The solutions aim to bypass the costly, time-intensive process of anti-idiotype antibody creation while streamlining workflows for researchers.</description><pubDate>Wed, 26 Feb 2025 14:49:25 +0000</pubDate></item><item><title>COTA Healthcare announces AI milestone in real-world oncology data</title><link>https://www.drugdiscoverytrends.com/cota-healthcare-announces-ai-milestone-in-real-world-oncology-data/</link><description>COTA Healthcare has introduced a groundbreaking generative AI platform designed to enhance the accuracy and profitability of large-scale real-world oncology data curation. This innovation signifies a notable advancement in automating the historically labor-intensive process of RWD abstraction in the oncology sector.</description><pubDate>Wed, 26 Feb 2025 19:00:13 +0000</pubDate></item><item><title>A B-vitamin rescues Parkinson-like damage in flies, pointing to new neuroprotective strategy</title><link>https://www.drugdiscoverytrends.com/a-b-vitamin-rescues-parkinson-like-damage-in-flies-pointing-to-new-neuroprotective-strategy/</link><description>A recent study published in Science Signaling highlights biotin (vitamin B7) as a promising neuroprotective agent against manganese-induced neurotoxicity associated with Parkinson's disease. Using fruit fly models and human dopaminergic neurons, researchers found that biotin supplementation effectively reverses neurologic damage from excessive manganese exposure.</description><pubDate>Thu, 27 Feb 2025 02:10:50 +0000</pubDate></item><item><title>Successful Scale-Up Of An Upstream Viral Vector Process Using An Adherent Platform</title><link>https://www.fiercebiotech.com/premium/webinar/1368645</link><description>Cytiva's webinar, featuring Brian Gardell, explores scaling challenges in viral vector manufacturing for cell and gene therapies, emphasizing the need for cost-effective, standardized processes to meet clinical demand. The session highlights a case study on successfully scaling a helper-dependent adenovirus (HDAd) production process from bench optimization to commercial readiness using adherent culture platforms.</description><pubDate>Thu, 27 Feb 2025 16:40:10 +0000</pubDate></item><item><title>Q&amp;A: AnaptysBio’s CMO on rosnilimab’s ‘compelling’ phase 2b RA results</title><link>https://www.drugdiscoverytrends.com/qa-anaptysbios-cmo-on-rosnilimabs-compelling-phase-2b-ra-results/</link><description>AnaptysBio has reported encouraging results from its Phase 2b RENOIR clinical trial for rosnilimab, with nearly 70% of participants achieving low disease activity by Week 14 and sustained improvements through Week 28. The therapy successfully met its primary endpoint, demonstrating significant efficacy compared to placebo in reducing disease activity scores.</description><pubDate>Fri, 28 Feb 2025 16:41:52 +0000</pubDate></item><item><title>Finding Patients, Closing Treatment Gaps, and Building Better Messaging through AI and Real-World Data</title><link>https://www.fiercebiotech.com/premium/webinar/1368842</link><description>OM1's upcoming webinar, featuring experts Joseph Zabinski and Kathryn Starzyk, explores how AI-driven digital phenotyping and real-world data can help pharmaceutical teams identify underserved patient populations and align therapies with unmet clinical needs. The session will demonstrate strategies to bridge treatment gaps, refine market messaging, and ensure therapies reach overlooked communities through advanced analytics.</description><pubDate>Thu, 06 Mar 2025 20:09:20 +0000</pubDate></item><item><title>J&amp;J Axes Late-Stage Depression Trial After Underwhelming Efficacy</title><link>https://www.biospace.com/drug-development/j-j-axes-late-stage-depression-trial-after-underwhelming-efficacy</link><description>Despite aticaprant's Phase III setback, analysts say J&amp;J's neuroscience strategy remains intact, bolstered by its recent $14.6 billion acquisition of Intra-Cellular Therapeutics. The company’s confidence is further reinforced by the continued success of Spravato, its treatment for resistant depression, positioning it to maintain momentum in the sector.</description><pubDate>Fri, 07 Mar 2025 13:46:12 +0000</pubDate></item><item><title>AstraZeneca Builds Stomach Cancer Case for Imfinzi With Strong Phase III Data</title><link>https://www.biospace.com/drug-development/astrazeneca-builds-stomach-cancer-case-for-imfinzi-with-strong-phase-iii-data</link><description>AstraZeneca's cancer drug Imfinzi is poised to drive significant growth in 2025, with regulators set to decide on its expanded use in treating stomach and bladder cancers. The blockbuster therapy generated over $4.7 billion in sales last year, cementing its role as a key revenue driver for the pharmaceutical giant.</description><pubDate>Fri, 07 Mar 2025 13:58:56 +0000</pubDate></item><item><title>Novo’s Studies of GLP-1s for Addiction Limited to Ongoing Phase II</title><link>https://www.biospace.com/drug-development/novos-studies-of-glp-1s-for-addiction-limited-to-ongoing-phase-ii</link><description>Novo Nordisk clarified it has no additional clinical trials exploring GLP-1 drugs for addiction beyond a Phase II study testing semaglutide and two other medications, despite recent speculation. The trial, which includes alcohol use disorder as a secondary endpoint, remains the sole focus for potential substance use applications, following a company official’s earlier comments.</description><pubDate>Fri, 07 Mar 2025 14:29:30 +0000</pubDate></item><item><title>At $300M Kardigan startup, former MyoKardia team unveils its first drug, and it comes from Ionis</title><link>https://endpts.com/at-300m-kardigan-startup-former-myokardia-team-unveils-its-first-drug-and-it-comes-from-ionis/</link><description>Former MyoKardia executives launched a heart health biotech startup with $300 million in funding, leveraging undisclosed partnerships to secure in-licensed clinical-stage assets for cardiac therapies. The stealth-mode company remains tight-lipped about specific deals but signals a focus on advancing innovative treatments, attracting attention for its seasoned leadership and strategic collaborations.</description><pubDate>Fri, 07 Mar 2025 16:16:52 +0000</pubDate></item><item><title>Roche launches new Boston center; NIH centralizes peer review</title><link>https://www.biopharmadive.com/news/roche-boston-center-nih-peer-review-pfizer-james-list/741901/</link><description>Swiss pharma giant Novartis announced plans to centralize its cardiometabolic drug research at a new Allston, Massachusetts, hub, signaling a strategic focus on heart and metabolic disease innovation. Meanwhile, AskBio progressed a mid-phase gene therapy trial, and Pfizer tapped a GLP-1 expert, intensifying competition in the weight-loss and diabetes therapeutics race.</description><pubDate>Fri, 07 Mar 2025 16:20:00 +0000</pubDate></item><item><title>J&amp;J scraps depression testing for potential blockbuster drug</title><link>https://www.biopharmadive.com/news/johnson-depression-studies-discontinue-aticaprant-neumora/741922/</link><description>A recent decision has dealt a "big blow" to a promising class of brain therapies, including Johnson &amp; Johnson’s experimental drug aticaprant and Neumora Therapeutics’ candidate, casting uncertainty over their development. While the article highlights setbacks for these specific treatments, it does not mention any new business deals, partnerships, or acquisitions related to the companies involved.</description><pubDate>Fri, 07 Mar 2025 17:08:00 +0000</pubDate></item><item><title>Multi-Modality Testing of EGFR</title><link>https://www.fiercebiotech.com/resource/multi-modality-testing-egfr</link><description>Neogenomics highlights its new white paper advocating a multi-modality testing approach to improve clinical trials, offering deeper insights into patient responses and treatment effectiveness. The sponsored resource, available for download, underscores how integrating diverse testing methods can advance oncology research and therapeutic outcomes.</description><pubDate>Fri, 07 Mar 2025 18:04:58 +0000</pubDate></item><item><title>FDA approves Neurotech therapy for rare eye disease</title><link>https://endpts.com/fda-approves-neurotech-therapy-for-rare-eye-disease/</link><description>The FDA approved Neurotech Pharmaceuticals’ first-of-its-kind cell therapy for macular telangiectasia type 2, a rare eye disease causing progressive central vision loss, marking a major advancement for patients with no prior treatment options. The therapy, which implants cells to repair retinal damage, could transform care for the condition, though the article does not mention specific business deals or partnerships related to its development.</description><pubDate>Fri, 07 Mar 2025 19:57:13 +0000</pubDate></item><item><title>Sun Pharma to acquire Checkpoint Therapeutics and its anti-PD-L1 antibody</title><link>https://endpts.com/sun-pharma-to-acquire-checkpoint-therapeutics-and-its-anti-pd-l1-antibody/</link><description>Checkpoint Therapeutics has pivoted from seeking a partnership for its newly approved cancer drug to being acquired outright by India’s Sun Pharma in a strategic immuno-oncology expansion. The deal, valued at $4.10 per share, marks a swift exit for Checkpoint and reinforces Sun Pharma’s growing footprint in cutting-edge cancer therapies.</description><pubDate>Mon, 10 Mar 2025 12:20:53 +0000</pubDate></item><item><title>Novo Nordisk’s CagriSema shows 15.7% weight loss in second pivotal trial</title><link>https://endpts.com/novo-nordisks-cagrisema-shows-15-7-weight-loss-in-second-pivotal-trial/</link><description>Novo Nordisk announced Monday that its drug CagriSema achieved 15.7% weight loss in patients with obesity and type 2 diabetes after over a year of use, marking a potential advancement in dual-treatment therapies. The result underscores the drug’s efficacy in addressing these interconnected conditions, positioning it as a promising contender in the competitive metabolic health market.</description><pubDate>Mon, 10 Mar 2025 12:21:18 +0000</pubDate></item><item><title>J&amp;J’s Oral IL-23R Blocker Sets New Standard in Plaque Psoriasis, Beating BMS’ Sotyktu</title><link>https://www.biospace.com/drug-development/j-js-oral-il-23r-blocker-sets-new-standard-in-plaque-psoriasis-beating-bmss-sotyktu</link><description>New late-stage trial data reveals Johnson &amp; Johnson’s psoriasis drug icotrokinra outperformed Bristol Myers Squibb’s Sotyktu in clearing skin and reducing symptom severity for patients with plaque psoriasis. The findings could intensify competition in the dermatology treatment market, positioning J&amp;J’s therapy as a potential challenger in this therapeutic area.</description><pubDate>Mon, 10 Mar 2025 14:03:00 +0000</pubDate></item><item><title>BMS’ Sotyktu Notches Phase III Win in Psoriatic Arthritis</title><link>https://www.biospace.com/drug-development/bms-sotyktu-notches-phase-iii-win-in-psoriatic-arthritis</link><description>In the plaque psoriasis market, Sotyktu is locked in a competitive battle with Amgen’s Otezla while bracing for new rivalry from Alumis’ investigational TYK2 inhibitor. The intensifying competition underscores the dynamic landscape of psoriasis treatments as emerging therapies threaten to disrupt established players.</description><pubDate>Mon, 10 Mar 2025 14:07:24 +0000</pubDate></item><item><title>Novo Dips After CagriSema’s Latest Lower-Than-Expected Weight Loss Readout</title><link>https://www.biospace.com/drug-development/novo-dips-after-cagrisemas-latest-lower-than-expected-weight-loss-readout</link><description>New clinical trial results revealed CagriSema, a weight-loss drug from Novo, achieved 15.7% weight reduction in diabetic patients over 68 weeks but delivered a disappointing 22.7% in non-diabetic patients by December 2024, falling short of the company’s projected 25% efficacy. The underwhelming performance in non-diabetic trials raises questions about the drug’s competitive edge in the crowded obesity treatment market.</description><pubDate>Mon, 10 Mar 2025 14:14:35 +0000</pubDate></item><item><title>Mineralys shares climb on study data for blood pressure drug</title><link>https://www.biopharmadive.com/news/mineralys-lorundrostat-hypertension-study-results/742000/</link><description>New studies on Mineralys' hypertension treatment have validated the drug as a promising near-commercial product, with analysts hailing it as a "derisked, almost-commercial stage cardiometabolic asset." While no specific deals or partnerships were mentioned, the data bolsters the therapy’s market potential and positions it for future commercial opportunities.</description><pubDate>Mon, 10 Mar 2025 15:30:00 +0000</pubDate></item><item><title>Trevi Therapeutics stock soars on Phase 2a chronic cough data</title><link>https://endpts.com/trevi-therapeutics-stock-soars-on-phase-2a-chronic-cough-data/</link><description>Trevi Therapeutics' chronic cough drug demonstrated a 57% reduction in 24-hour cough frequency versus placebo in a Phase 2a trial, outperforming investor expectations and sparking a 40% surge in its stock ($TRVI) at market open. The breakthrough underscores the treatment’s potential and has ignited optimism among investors about the company’s clinical and commercial prospects.</description><pubDate>Mon, 10 Mar 2025 15:51:40 +0000</pubDate></item><item><title>J&amp;J, Protagonist outline first IBD win for potential immunological blockbuster</title><link>https://endpts.com/jj-protagonist-outline-first-ibd-win-for-potential-immunological-blockbuster/</link><description>Johnson &amp; Johnson and Protagonist Therapeutics have partnered to develop an oral IL-23 drug, aiming to create a breakthrough immunology treatment. The companies announced progress toward this goal on Monday, signaling potential advancements in bringing the blockbuster drug candidate closer to market.</description><pubDate>Mon, 10 Mar 2025 16:04:34 +0000</pubDate></item><item><title>Mineralys’ Hypertension Drug Drops Blood Pressure in Phase II/III, Setting Up Market Clash</title><link>https://www.biospace.com/drug-development/mineralys-hypertension-drug-drops-blood-pressure-in-phase-ii-iii-setting-up-market-clash</link><description>Mineralys Therapeutics saw its stock surge over 50% after announcing successful Phase 2 trial results for its hypertension drug, which significantly reduced blood pressure in patients across two clinical studies. The promising data positions the therapy as a potential leader in the $30 billion hypertension market, heightening investor interest in the company’s future regulatory and commercial plans.</description><pubDate>Mon, 10 Mar 2025 16:11:28 +0000</pubDate></item><item><title>Mired in low expectations, Novo braces for upcoming CagriSema head-to-head trial</title><link>https://endpts.com/mired-in-low-expectations-novo-braces-for-upcoming-cagrisema-head-to-head-trial/</link><description>Novo Nordisk's weight loss drug CagriSema underperformed in late-stage trials, missing analyst expectations and marking its second high-profile clinical setback. With mounting pressure on the candidate, its success in future trials has become critical for the company’s competitive pipeline.</description><pubDate>Mon, 10 Mar 2025 16:20:49 +0000</pubDate></item><item><title>#AAD25 roundup: Data from Amgen, Bristol Myers, J&amp;J, Alumis and more</title><link>https://endpts.com/aad25-roundup-data-from-amgen-bristol-myers-jj-alumis-and-more/</link><description>At the American Academy of Dermatology annual meeting, key players like Amgen, Bristol Myers Squibb, Alumis, and Kyowa Kirin spotlighted updates on their dermatology drug pipelines, though no mergers or acquisitions were highlighted. The event emphasized breakthroughs in treatments for conditions like psoriasis and eczema, showcasing the industry’s focus on advancing innovative therapies for skin diseases.</description><pubDate>Mon, 10 Mar 2025 16:37:26 +0000</pubDate></item><item><title>Deep Dive: Cardiovascular Disease Back in the Spotlight</title><link>https://www.biospace.com/drug-development/deep-dive-cardiovascular-disease-back-in-the-spotlight</link><description>BioSpace highlights the rapid evolution of emerging therapeutic modalities, from gene editing to cell therapies, as biotech and pharma companies race to innovate in a competitive market. The article underscores the intensifying battles for dominance in this space, with advancements poised to reshape treatment paradigms and spur significant industry growth.</description><pubDate>Mon, 10 Mar 2025 16:40:00 +0000</pubDate></item><item><title>Beam shares promising first clinical data on gene editing treatment</title><link>https://endpts.com/beam-shares-promising-first-clinical-data-on-gene-editing-treatment/</link><description>Beam Therapeutics' experimental gene-editing therapy demonstrated promising results in a small trial, reducing mutant proteins linked to lung-damaging alpha-1 antitrypsin deficiency and boosting corrected protein levels in nine participants. The early data underscores the treatment's potential as a one-time fix for the genetic disorder, though the article does not mention any business deals, partnerships, or mergers.</description><pubDate>Mon, 10 Mar 2025 16:42:30 +0000</pubDate></item><item><title>Novo’s Wegovy successor disappoints in second large trial</title><link>https://www.biopharmadive.com/news/novo-nordisk-cagrisema-study-results-diabetes-weight-loss/742008/</link><description>A recent study found that CagriSema, a weight-loss therapy for individuals with obesity and diabetes, demonstrated effectiveness in aiding weight loss but fell short of outperforming Eli Lilly’s rival drug Zepbound. While the results highlight CagriSema’s potential, they solidify Zepbound’s competitive edge in the burgeoning metabolic treatment market.</description><pubDate>Mon, 10 Mar 2025 17:17:00 +0000</pubDate></item><item><title>Beam base editing therapy gets ‘proof of concept’ in rare lung disease</title><link>https://www.biopharmadive.com/news/beam-aatd-base-editing-initial-data-results-302/742015/</link><description>Beam Therapeutics' shares dropped sharply despite promising early study results showing its gene-editing technology could address the genetic cause of alpha-1 antitrypsin deficiency. The stock decline highlights investor concerns even as the company advances its innovative treatment potential.</description><pubDate>Mon, 10 Mar 2025 17:25:00 +0000</pubDate></item><item><title>BioNTech's shares dip after posting lukewarm revenue guidance</title><link>https://endpts.com/biontechs-shares-dip-after-posting-lukewarm-revenue-guidance/</link><description>BioNTech shares fell 2% after projecting lower 2025 revenues, citing reduced COVID-19 vaccine demand and oversupply challenges despite a solid $4.2 billion revenue in 2023. The company plans to pivot toward advancing cancer treatments and cost-cutting measures while preparing for new vaccine launches to offset declining pandemic-related sales.</description><pubDate>Mon, 10 Mar 2025 19:37:01 +0000</pubDate></item><item><title>Making Just-in-Time Oncology Trials Work: Overcoming Barriers and Unlocking Potential</title><link>https://www.fiercebiotech.com/premium/webinar/1368918</link><description>Just-in-time (JIT) oncology trials aim to accelerate research and improve patient access by activating trial sites only after identifying eligible patients, requiring strong collaboration between sponsors, sites, and IRBs to streamline processes and pre-negotiate agreements. An upcoming webinar will explore strategies like data-driven prescreening, standardized protocols, and centralized oversight to overcome operational barriers and expand the use of JIT trials in delivering faster, cost-effective cancer treatments.</description><pubDate>Mon, 10 Mar 2025 19:50:06 +0000</pubDate></item><item><title>New Flagship startup aims to trailblaze ‘AI science factories’</title><link>https://endpts.com/new-flagship-startup-aims-to-trailblaze-ai-science-factories/</link><description>Flagship Pioneering unveiled Lila Sciences, a new startup backed by $200 million, aiming to develop "scientific superintelligence" by integrating AI with cutting-edge scientific research. The venture assembles a cross-disciplinary team of scientists and AI experts under Flagship’s venture-creation model to accelerate transformative breakthroughs in biotechnology and drug discovery.</description><pubDate>Mon, 10 Mar 2025 20:39:42 +0000</pubDate></item><item><title>The true cost of steroid-toxicity</title><link>https://www.drugdiscoverytrends.com/the-true-cost-of-steroid-toxicity/</link><description>Glucocorticoids, often called steroids, remain the standard treatment for various autoimmune disorders due to their effectiveness in rapidly alleviating inflammation and symptoms. However, the long-term toxicity associated with their use may lead to significant hidden costs in patient management and healthcare systems.</description><pubDate>Tue, 11 Mar 2025 01:33:58 +0000</pubDate></item><item><title>Bristol Myers buys out cell therapy partner 2seventy bio</title><link>https://endpts.com/bristol-myers-buys-out-cell-therapy-partner-2seventy-bio/</link><description>Bristol Myers Squibb has agreed to acquire 2seventy bio, its longtime partner in developing the CAR-T cell therapy Abecma for multiple myeloma, in a $286 million all-cash deal. The acquisition strengthens Bristol Myers' foothold in cancer therapies, building on the companies' existing collaboration aimed at advancing cutting-edge immunocellular treatments.</description><pubDate>Tue, 11 Mar 2025 08:13:39 +0000</pubDate></item><item><title>Arvinas and Pfizer’s PROTAC vepdegestrant works in subset of breast cancer patients</title><link>https://endpts.com/arvinas-and-pfizers-protac-vepdegestrant-works-in-subset-of-breast-cancer-patients/</link><description>Arvinas and Pfizer's partnered experimental breast cancer drug, vepdegestrant, failed to outperform existing therapies in the Phase 3 VERITAC-2 trial, casting doubt on its competitive potential. The results highlight challenges for the collaboration’s aim to deliver a differentiated treatment in the crowded protein degrader landscape.</description><pubDate>Tue, 11 Mar 2025 11:56:49 +0000</pubDate></item><item><title>Beam’s Gene Editor Achieves ‘First Ever’ Genetic Correction in AATD</title><link>https://www.biospace.com/drug-development/beams-gene-editor-achieves-first-ever-genetic-correction-in-aatd</link><description>William Blair analysts highlighted BEAM-302 as a breakthrough therapy, praising its superior efficacy in its sector in a recent investor note. While the report emphasized the drug's potential to redefine treatment standards, it did not mention any specific business deals, partnerships, or acquisitions related to the product.</description><pubDate>Tue, 11 Mar 2025 13:52:59 +0000</pubDate></item><item><title>The Shape of a Pandemic: Boom, Bust and Recover</title><link>https://www.biospace.com/business/the-shape-of-a-pandemic-boom-bust-and-recover</link><description>As the world marks five years since the onset of COVID-19, the pandemic’s ripple effects continue to reshape global health, innovation, and daily life, with the life sciences sector undergoing unprecedented transformation. While no specific business deals are cited, the article underscores how the crisis catalyzed lasting shifts in biomedical research, public health strategies, and societal resilience, leaving a profound legacy of change for individuals and industries alike.</description><pubDate>Tue, 11 Mar 2025 13:56:41 +0000</pubDate></item><item><title>Pfizer, Arvinas Post Mixed Late-Stage Breast Cancer Data for Closely Watched PROTAC Drug</title><link>https://www.biospace.com/drug-development/pfizer-arvinas-post-mixed-late-stage-breast-cancer-data-for-closely-watched-protac-drug</link><description>Vepdegestrant’s mixed trial results—stalling on broad progression-free survival but showing promise in a niche patient group—sparked a 43% plunge in Arvinas’ stock, with analysts casting doubt on the drug's long-term viability. While no new deals were announced, the setback raises questions about the company’s ability to attract future partnerships or advance the drug’s commercial prospects.</description><pubDate>Tue, 11 Mar 2025 14:08:28 +0000</pubDate></item><item><title>Corrected: Merck opens billion-dollar US facility to make Gardasil</title><link>https://endpts.com/merck-opens-billion-dollar-facility-to-make-bladder-cancer-immunotherapy/</link><description>Merck has launched a new North Carolina-based manufacturing facility to produce HPV vaccines, including Gardasil and Gardasil 9, to meet rising global demand for cervical cancer prevention. The plant’s opening aligns with Merck’s strategy to expand production capacity amid increasing vaccine rollout efforts worldwide.</description><pubDate>Tue, 11 Mar 2025 14:50:06 +0000</pubDate></item><item><title>2seventy bio, Bluebird’s cell therapy spinout, sells to Bristol Myers for less than $300M</title><link>https://www.biopharmadive.com/news/2seventy-bio-bristol-myers-deal-abecma-bluebird/742142/</link><description>2Seventy Bio's recent acquisition has terminated its brief stint as an independent firm, marking the end of a turbulent period marked by strategic restructuring and asset sales. The company, which shed research segments and saw its market value plummet by nearly 100%, now shifts focus under new ownership amid financial struggles.</description><pubDate>Tue, 11 Mar 2025 16:05:00 +0000</pubDate></item><item><title>Arvinas gets positive breast cancer data, but finds differentiation a hard sell</title><link>https://www.biopharmadive.com/news/arvinas-pfizer-vepdegestrant-breast-cancer-data-veritac/742135/</link><description>Arvinas and Pfizer's partnered breast cancer drug, vepdegestrant, showed promising results in a specific patient subgroup compared to fulvestrant, though it didn't meet overall trial goals. The mixed outcomes highlight the experimental therapy's potential niche benefits while underscoring the challenges of broad efficacy in cancer treatment.</description><pubDate>Tue, 11 Mar 2025 16:45:00 +0000</pubDate></item><item><title>Viking inks CordenPharma deal to boost obesity drug supply</title><link>https://www.biopharmadive.com/news/viking-cordenpharma-obesity-drug-manufacturing-deal/742139/</link><description>A biotech firm is investing $150 million in a strategic alliance to secure expanded production capacity for a high-profile weight-loss therapy, positioning itself to meet soaring demand. The partnership underscores the company’s aggressive push to capitalize on the competitive but rapidly growing market for obesity treatments.</description><pubDate>Tue, 11 Mar 2025 17:25:00 +0000</pubDate></item><item><title>Agenus CMO touts immunotherapy advances on The Top Line</title><link>https://www.fiercebiotech.com/sponsored/agenus-cmo-touts-immunotherapy-advances-top-line</link><description>Agenus' Chief Medical Officer highlighted the company's recent advancements in immunotherapy during an appearance on "The Top Line," emphasizing the positive impact on patient treatment options. The update reflects Agenus' commitment to innovative cancer therapies and its ongoing research efforts in the field.</description><pubDate>Tue, 11 Mar 2025 17:26:30 +0000</pubDate></item><item><title>How biosimulation and virtual trials can bust through clinical trial roadblocks</title><link>https://www.drugdiscoverytrends.com/how-biosimulation-and-virtual-trials-can-bust-through-clinical-trial-roadblocks/</link><description>Over 300 million people globally suffer from rare diseases, with about 95% lacking FDA-approved treatments, presenting significant challenges for traditional clinical trials due to small patient populations. Innovative biosimulation and virtual trial methods are emerging as promising solutions to overcome these obstacles, according to Oxana Iliach, vice-chair.</description><pubDate>Fri, 14 Mar 2025 15:54:00 +0000</pubDate></item><item><title>Advancing the Future of Biomarker-Driven Immunotherapy</title><link>https://www.fiercebiotech.com/premium/webinar/1369042</link><description>Join an upcoming webinar on the DUTRENEO trial, highlighting innovative approaches in spatial biomarkers and multi-omics for improving patient stratification in neoadjuvant therapy for muscle-invasive bladder cancer. Experts will discuss the challenges of traditional biomarkers and the potential of integrating multi-modal strategies to enhance therapeutic selection in future clinical trials.</description><pubDate>Fri, 14 Mar 2025 17:43:32 +0000</pubDate></item><item><title>5 CAR T Cell Therapies With Autoimmune Readouts in 2025</title><link>https://www.biospace.com/drug-development/5-car-t-cell-therapies-with-autoimmune-readouts-in-2025</link><description>Biopharma is expanding the application of CAR T therapies from cancer treatments to targeting autoimmune disorders, with multiple early- to mid-stage results anticipated in the coming year. This strategic shift highlights the industry's ongoing innovation and commitment to addressing diverse medical challenges.</description><pubDate>Mon, 17 Mar 2025 04:01:00 +0000</pubDate></item><item><title>Dyne's Duchenne Exon Skipping Oligomer Shows 'Differentiated' Clinical Effect</title><link>https://www.biospace.com/drug-development/dynes-duchenne-exon-skipping-oligomer-shows-differentiated-clinical-effect</link><description>Dyne plans to file for accelerated approval of its gene therapy DYNE-251 by early 2026, targeting a patient population suitable for exon 51 skipping. This move positions DYNE-251 in direct competition with Sarepta's Exondys 51.</description><pubDate>Mon, 17 Mar 2025 12:30:46 +0000</pubDate></item><item><title>Orca Bio to seek approval of T cell transplant after positive trial data</title><link>https://www.biopharmadive.com/news/orca-bio-t-cell-therapy-transplant-aml-study-results/742667/</link><description>Orca's innovative treatment, which utilizes a purified mix of donor-derived T cells and stem cells, demonstrated a better safety profile compared to traditional transplants for certain blood cancers. This promising approach could reshape treatment protocols, enhancing patient outcomes in the field of oncology.</description><pubDate>Mon, 17 Mar 2025 15:30:00 +0000</pubDate></item><item><title>Taiho buys Swiss biotech and its ADC tech for $400M</title><link>https://www.biopharmadive.com/news/taiho-araris-acquire-antibody-drug-conjugate-adc-linker/742666/</link><description>The pharmaceutical company is set to acquire Araris Biotech to enhance its portfolio with three preclinical antibody-drug conjugates (ADCs) and a linking technology that Araris touts as superior to current options. This acquisition aims to strengthen the company's capabilities in the innovative biopharmaceutical sector.</description><pubDate>Mon, 17 Mar 2025 16:13:32 +0000</pubDate></item><item><title>AstraZeneca inks deal with Alteogen for subcutaneous cancer drugs</title><link>https://endpts.com/astrazeneca-inks-deal-with-alteogen-for-subcutaneous-cancer-drugs/</link><description>AstraZeneca is investing approximately $1.35 billion in Korean biotech Alteogen to develop under-the-skin formulations for various oncology therapies. As part of this collaboration, AstraZeneca will license the ALT-B4 compound, which utilizes a specific enzyme for enhanced delivery.</description><pubDate>Mon, 17 Mar 2025 19:40:49 +0000</pubDate></item><item><title>Investigating key strategies for optimising clinical trial supply chains in 2025</title><link>https://www.pharmaceutical-technology.com/news/investigating-key-strategies-for-optimising-clinical-trial-supply-chains-in-2025/</link><description>At the 2025 Clinical Trial Supply New England conference, experts will share insights and strategies to enhance the efficiency of clinical supply chains. The focus will be on innovative approaches to meet the evolving challenges in clinical trial logistics.</description><pubDate>Mon, 17 Mar 2025 20:41:28 +0000</pubDate></item><item><title>How Proscia is using AI embeddings to transform drug discovery in pathology</title><link>https://www.drugdiscoverytrends.com/how-proscia-is-using-ai-embeddings-to-transform-drug-discovery-in-pathology/</link><description>Proscia is leveraging AI-powered pathology analysis to enhance drug discovery by identifying patients who would benefit from a lung cancer drug candidate that was previously on the verge of being abandoned. The development of a machine learning algorithm allows researchers to distinguish between responders and non-responders, showcasing the transformative potential of AI in clinical applications.</description><pubDate>Mon, 17 Mar 2025 20:43:21 +0000</pubDate></item><item><title>University of Ottawa students harness tobacco relative to grow Ozempic-like drugs</title><link>https://www.drugdiscoverytrends.com/university-of-ottawa-students-harness-tobacco-relative-to-grow-ozempic-like-drugs/</link><description>University of Ottawa students are developing a method to produce peptide-based diabetes and weight-loss medications, similar to Ozempic, using the Nicotiana benthamiana plant. This innovative approach aims to address ongoing drug shortages and enhance the availability of these critical treatments.</description><pubDate>Tue, 18 Mar 2025 03:47:45 +0000</pubDate></item><item><title>CRISPR startup Arbor Biotechnologies raises $73.9M as it nears first trial</title><link>https://endpts.com/crispr-startup-arbor-raises-73-9m-as-it-nears-first-trial/</link><description>Arbor Biotechnologies has successfully secured $73.9 million in Series C financing to advance its first therapy into clinical trials, aimed at prevention. Founded by CRISPR pioneer Feng Zhang, the startup is poised to make significant contributions to the biotech field with this funding.</description><pubDate>Tue, 18 Mar 2025 10:30:00 +0000</pubDate></item><item><title>Arbor raises $74M amid genetic medicine’s funding slump</title><link>https://www.biopharmadive.com/news/arbor-biotechnologies-series-b-gene-editing-primary-hyperoxaluria/742625/</link><description>A recent funding round will support the development of a "one-and-done" treatment for a rare kidney condition, which aims to alleviate patient concerns associated with existing therapies from Alnylam and Novo Nordisk. The CEO emphasized this innovative approach in addressing the specific needs of patients.</description><pubDate>Tue, 18 Mar 2025 10:30:00 +0000</pubDate></item><item><title>Health Canada approves Biogen’s Skyclarys for Friedreich’s ataxia</title><link>https://www.pharmaceutical-technology.com/news/health-canada-biogen-skyclarys/</link><description>Health Canada has approved Biogen's Skyclarys as a treatment for Friedreich's ataxia in patients aged 16 and older. This landmark decision marks a significant advancement in the management of this rare neuromuscular disorder.</description><pubDate>Tue, 18 Mar 2025 10:35:27 +0000</pubDate></item><item><title>Japan's RegCell raises $45.8M for Treg cell therapies, will move to US</title><link>https://endpts.com/japans-regcell-raises-45-8m-for-treg-cell-therapies-will-move-to-us/</link><description>Cell therapy biotech RegCell has successfully raised $45.8 million to advance its efforts in developing new cell therapies for autoimmune conditions, aiming to connect Japanese scientific innovations with the US biotech sector. This funding includes $8.5 million in investments, positioning RegCell to enhance its research and development initiatives.</description><pubDate>Tue, 18 Mar 2025 12:00:02 +0000</pubDate></item><item><title>Duchenne patient dies after receiving Sarepta gene therapy</title><link>https://www.biopharmadive.com/news/sarepta-elevidys-duchenne-gene-therapy-death-liver-failure/742765/</link><description>A young man who received the gene therapy Elevidys has died from acute liver failure, raising concerns among analysts about the safety of the treatment. This incident may lead healthcare professionals to reconsider prescribing Elevidys in future cases.</description><pubDate>Tue, 18 Mar 2025 14:20:00 +0000</pubDate></item><item><title>Opko and Entera focus on oral care for obesity and metabolic disorders</title><link>https://www.pharmaceutical-technology.com/news/opko-entera-oral-treatment-metabolic-disorders/</link><description>Opko Health has entered into a partnership and license agreement with Entera Bio to advance the development of an oral dual agonist GLP-1. This collaboration aims to accelerate the research and potential commercialization of this innovative therapeutic approach.</description><pubDate>Tue, 18 Mar 2025 14:37:07 +0000</pubDate></item><item><title>Sofinnova’s latest biotech fund sprouts three new startups</title><link>https://www.biopharmadive.com/news/sofinnova-fund-startups-bioclec-signadori-forth/742816/</link><description>Sofinnova is supporting startups focused on innovative therapies for fibrosis, cancer, and Alzheimer's as part of its pan-European strategy. This initiative underscores its commitment to advancing healthcare solutions across the continent.</description><pubDate>Tue, 18 Mar 2025 15:50:25 +0000</pubDate></item><item><title>Prime sets sights on liver, lung disease as next target for its gene editing tech</title><link>https://www.biopharmadive.com/news/prime-medicine-aatd-gene-editing-testing-plans/742798/</link><description>The biotech has launched a new research program targeting alpha-1 antitrypsin deficiency, a condition that is also being investigated by competitor Beam Therapeutics. This move aims to strengthen the company's position in the competitive landscape of biotech research.</description><pubDate>Tue, 18 Mar 2025 16:09:00 +0000</pubDate></item><item><title>Spatial biology: Transforming our understanding of cellular environments</title><link>https://www.drugdiscoverytrends.com/spatial-biology-transforming-our-understanding-of-cellular-environments/</link><description>Spatial biology is transforming the study of cellular interactions by employing advanced imaging and molecular techniques to visualize and map the localization of cells and their components within tissues. This innovative approach enhances our understanding of how cells interact with their environments, marking a significant shift from traditional biological research methods.</description><pubDate>Tue, 18 Mar 2025 23:45:32 +0000</pubDate></item><item><title>GLP-1 Drug Boom Recalls the Rise of PD-1 Checkpoint Inhibitors</title><link>https://www.biospace.com/business/glp-1-drug-boom-recalls-the-rise-of-pd-1-checkpoint-inhibitors</link><description>The surge in GLP-1 weight loss drugs mirrors the early success of PD-1 inhibitors, yet significant market differences indicate that the outcomes may differ this time. Experts caution that while the current excitement is high, varied factors could impact the long-term trajectory of these weight-loss treatments.</description><pubDate>Wed, 19 Mar 2025 06:11:00 +0000</pubDate></item><item><title>Arbor to advance gene editing treatments with $73.9m funding</title><link>https://www.pharmaceutical-technology.com/news/arbor-gene-editing-treatments/</link><description>Arbor Biotechnologies has secured $73.9 million to advance its gene editing therapeutic pipeline, focusing on treatments for liver and central nervous system diseases. The funding will support the development of innovative therapies in these critical areas of healthcare.</description><pubDate>Wed, 19 Mar 2025 08:28:17 +0000</pubDate></item><item><title>Novartis sheds staff as Entresto patent expiry looms</title><link>https://pharmaphorum.com/news/novartis-sheds-staff-entresto-patent-expiry-looms</link><description>Novartis is set to lay off 427 employees in the US in anticipation of the impending loss of market exclusivity for its leading heart failure treatment, Entresto. This strategic move reflects the company's efforts to adjust to the competitive landscape in the pharmaceutical sector as generic alternatives become available.</description><pubDate>Wed, 19 Mar 2025 09:30:08 +0000</pubDate></item><item><title>Insight and insitro partner on AI model to seek ocular biomarkers</title><link>https://www.pharmaceutical-technology.com/news/insight-insitro-ai-model/</link><description>Insight Health Data Research Hub and insitro have formed a partnership to create an AI foundation model focused on ocular biomarkers. This collaboration aims to enhance the understanding and development of eye-related healthcare solutions through advanced data analysis.</description><pubDate>Wed, 19 Mar 2025 10:47:43 +0000</pubDate></item><item><title>Servier licenses Black Diamond’s RAS- and RAF-targeted drug</title><link>https://endpts.com/servier-pays-70m-upfront-for-black-diamonds-ras-and-raf-targeted-cancer-drug/</link><description>Black Diamond Therapeutics has sold an early-stage targeted cancer drug to Servier, redirecting its focus towards a next-generation lung cancer therapy. This strategic move allows Black Diamond to allocate its resources more effectively while still advancing its cancer treatment portfolio.</description><pubDate>Wed, 19 Mar 2025 11:00:13 +0000</pubDate></item><item><title>Roche inks $1B+ biobucks deal with Oxford BioTherapeutics for new antibody cancer targets</title><link>https://endpts.com/roche-inks-1b-biobucks-deal-with-oxford-biotherapeutics-for-new-antibody-cancer-targets/</link><description>Roche has established a multiyear partnership with Oxford BioTherapeutics aimed at identifying new targets for antibody-based cancer treatments, featuring an upfront payment of $36 million. This collaboration will leverage the strengths of both companies to enhance cancer treatment options.</description><pubDate>Wed, 19 Mar 2025 11:05:26 +0000</pubDate></item><item><title>Updated: Immunovant will not take rare disease drug to regulators despite Phase 3 win</title><link>https://endpts.com/immunovant-will-not-take-immune-drug-to-regulators-despite-phase-3-success/</link><description>Immunovant has decided not to pursue approval for its candidate aimed at treating the autoimmune disorder myasthenia gravis (MG), despite positive results from its pivotal trial. The company announced this decision on Wednesday, indicating a shift in its clinical strategy.</description><pubDate>Wed, 19 Mar 2025 11:56:26 +0000</pubDate></item><item><title>Google promises new AI models for drug discovery</title><link>https://pharmaphorum.com/news/google-promises-new-ai-models-drug-discovery</link><description>Google is set to launch new open-source AI models for drug discovery, named TxGemma, as part of a developers' programme later this month. This initiative aims to enhance research and innovation in the pharmaceutical industry.</description><pubDate>Wed, 19 Mar 2025 13:00:36 +0000</pubDate></item><item><title>Roche taps Oxford BioTherapeutics for cancer drug discovery</title><link>https://pharmaphorum.com/news/roche-taps-oxford-biotherapeutics-cancer-drug-discovery</link><description>Oxford BioTherapeutics has secured a $1 billion partnership with Roche to enhance its drug discovery platform in oncology. This significant collaboration marks another milestone for the company in advancing cancer therapies.</description><pubDate>Wed, 19 Mar 2025 13:57:04 +0000</pubDate></item><item><title>Cargo shelves cell therapy research, lays off more staff</title><link>https://www.biopharmadive.com/news/cargo-layoffs-restructure-car-t-reverse-merger/742893/</link><description>CEO Gina Chapman is leaving the company as it explores options for a reverse merger or potential business combination. This strategic move signals a shift in company direction amid leadership changes.</description><pubDate>Wed, 19 Mar 2025 14:21:36 +0000</pubDate></item><item><title>Servier Nabs Solid Tumor Asset in up to $780M Deal With Black Diamond</title><link>https://www.biospace.com/deals/black-diamond-nabs-solid-tumor-asset-in-up-to-780m-deal-with-servier</link><description>The French pharmaceutical company has acquired Black Diamond's de-prioritized molecule for treating non-small cell lung cancers with specific mutations, which had seen its development halted to cut costs. This strategic move enhances the company's oncology portfolio amidst ongoing challenges in the market.</description><pubDate>Wed, 19 Mar 2025 14:24:52 +0000</pubDate></item><item><title>Ahead of FDA decision, Alnylam faces the big question: Can it make money?</title><link>https://endpts.com/ahead-of-fda-decision-alnylam-faces-the-big-question-can-it-make-money/</link><description>Alnylam, a leader in RNAi drug development, has successfully launched four therapies but remains unprofitable; however, it is poised for a potential turnaround as the FDA is set to decide on the approval of its new treatment by Sunday. This decision could significantly impact the company's financial outlook moving forward.</description><pubDate>Wed, 19 Mar 2025 15:24:19 +0000</pubDate></item><item><title>Cargo Therapeutics scraps R&amp;D pipeline, axes bulk of workforce as it looks for an exit</title><link>https://endpts.com/cargo-therapeutics-scraps-rd-pipeline-axes-bulk-of-workforce-as-it-looks-for-an-exit/</link><description>Cargo Therapeutics is terminating its remaining clinical programs and conducting significant layoffs as it seeks a permanent resolution to its ongoing troubles. This move marks the company's second round of workforce reductions as it faces challenges in the biotech sector.</description><pubDate>Wed, 19 Mar 2025 15:25:39 +0000</pubDate></item><item><title>Immunovant claims study success for immune disease drug but holds off on submission</title><link>https://www.biopharmadive.com/news/immunovant-roivant-batoclimab-myasthenia-gravis-1402-data/742921/</link><description>The company is actively progressing its next-generation drug as it completes testing for batoclimab in thyroid eye disease. This focus highlights their commitment to advancing innovative treatments in the healthcare sector.</description><pubDate>Wed, 19 Mar 2025 15:45:00 +0000</pubDate></item><item><title>Optum Rx says it will eliminate some prior authorization requirements</title><link>https://www.biopharmadive.com/news/optum-rx-eliminate-prior-authorizations/742964/</link><description>The PBM will eliminate the need for coverage reauthorization on approximately 80 drugs, notably including Vertex's cystic fibrosis medicines and various treatments for multiple sclerosis. This decision aims to enhance patient access and streamline the prescribing process for these critical medications.</description><pubDate>Wed, 19 Mar 2025 16:07:00 +0000</pubDate></item><item><title>Novartis’ Intrathecal Zolgensma Effective in Older Children</title><link>https://www.biospace.com/drug-development/Novartis-intrathecal-zolgensma-effective-in-older-children</link><description>Novartis is launching an intrathecal formulation of Zolgensma, expanding its reach to older patients with spinal muscular atrophy after the drug's successful market introduction in 2019. This new formulation aims to enhance treatment options and improve outcomes for individuals affected by this rare genetic condition.</description><pubDate>Wed, 19 Mar 2025 20:32:50 +0000</pubDate></item></channel></rss>